🚀 VC round data is live in beta, check it out!
Aurisco Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aurisco Pharmaceutical and similar public comparables like Jubilant Pharmova, Granules India, Sino Biological, Syngene and more.
Aurisco Pharmaceutical Overview
About Aurisco Pharmaceutical
Aurisco Pharmaceutical Co Ltd is engaged in production and sales of specialty APIs and pharmaceutical intermediates. The company's products include API's and Intermediates. Its products are supplied to Asia, Europe, America and Middle East through a well-established sales network.
Founded
1998
HQ
Employees
N/A
Website
Financials (LTM)
EV
$2B
Aurisco Pharmaceutical Financials
Aurisco Pharmaceutical reported last 12-month revenue of $256M and EBITDA of $90M.
In the same LTM period, Aurisco Pharmaceutical generated $152M in gross profit, $90M in EBITDA, and $69M in net income.
Revenue (LTM)
Aurisco Pharmaceutical P&L
In the most recent fiscal year, Aurisco Pharmaceutical reported revenue of $212M and EBITDA of $74M.
Aurisco Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $256M | XXX | $212M | XXX | XXX | XXX |
| Gross Profit | $152M | XXX | $124M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $90M | XXX | $74M | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 35% | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $69M | XXX | $51M | XXX | XXX | XXX |
| Net Margin | 27% | XXX | 24% | XXX | XXX | XXX |
| Net Debt | — | — | $23M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aurisco Pharmaceutical Stock Performance
Aurisco Pharmaceutical has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Aurisco Pharmaceutical's stock price is $3.81.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.9% | XXX | XXX | XXX | $0.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAurisco Pharmaceutical Valuation Multiples
Aurisco Pharmaceutical trades at 6.0x EV/Revenue multiple, and 17.2x EV/EBITDA.
EV / Revenue (LTM)
Aurisco Pharmaceutical Financial Valuation Multiples
As of March 18, 2026, Aurisco Pharmaceutical has market cap of $2B and EV of $2B.
Equity research analysts estimate Aurisco Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aurisco Pharmaceutical has a P/E ratio of 22.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 7.3x | XXX | XXX | XXX |
| EV/EBITDA | 17.2x | XXX | 21.0x | XXX | XXX | XXX |
| EV/EBIT | 19.0x | XXX | 26.0x | XXX | XXX | XXX |
| EV/Gross Profit | 10.1x | XXX | 12.4x | XXX | XXX | XXX |
| P/E | 22.4x | XXX | 30.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (51.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aurisco Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aurisco Pharmaceutical Margins & Growth Rates
Aurisco Pharmaceutical's revenue in the last 12 month grew by 17%.
Aurisco Pharmaceutical's rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aurisco Pharmaceutical's rule of X is 76% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Aurisco Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 52% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 76% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aurisco Pharmaceutical Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Granules India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sino Biological | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene | XXX | XXX | XXX | XXX | XXX | XXX |
| ACROBiosystems | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aurisco Pharmaceutical M&A Activity
Aurisco Pharmaceutical acquired XXX companies to date.
Last acquisition by Aurisco Pharmaceutical was on XXXXXXXX, XXXXX. Aurisco Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aurisco Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAurisco Pharmaceutical Investment Activity
Aurisco Pharmaceutical invested in XXX companies to date.
Aurisco Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Aurisco Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aurisco Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aurisco Pharmaceutical
| When was Aurisco Pharmaceutical founded? | Aurisco Pharmaceutical was founded in 1998. |
| Where is Aurisco Pharmaceutical headquartered? | Aurisco Pharmaceutical is headquartered in China. |
| Is Aurisco Pharmaceutical publicly listed? | Yes, Aurisco Pharmaceutical is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Aurisco Pharmaceutical? | Aurisco Pharmaceutical trades under 605116 ticker. |
| When did Aurisco Pharmaceutical go public? | Aurisco Pharmaceutical went public in 2020. |
| Who are competitors of Aurisco Pharmaceutical? | Aurisco Pharmaceutical main competitors are Jubilant Pharmova, Granules India, Sino Biological, Syngene. |
| What is the current market cap of Aurisco Pharmaceutical? | Aurisco Pharmaceutical's current market cap is $2B. |
| What is the current revenue of Aurisco Pharmaceutical? | Aurisco Pharmaceutical's last 12 months revenue is $256M. |
| What is the current revenue growth of Aurisco Pharmaceutical? | Aurisco Pharmaceutical revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Aurisco Pharmaceutical? | Current revenue multiple of Aurisco Pharmaceutical is 6.0x. |
| Is Aurisco Pharmaceutical profitable? | Yes, Aurisco Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aurisco Pharmaceutical? | Aurisco Pharmaceutical's last 12 months EBITDA is $90M. |
| What is Aurisco Pharmaceutical's EBITDA margin? | Aurisco Pharmaceutical's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Aurisco Pharmaceutical? | Current EBITDA multiple of Aurisco Pharmaceutical is 17.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.